الصفحة الرئيسية>>Signaling Pathways>> JAK/STAT Signaling>> EGFR>>Panitumumab

Panitumumab (Synonyms: ABX-EGF)

رقم الكتالوجGC66405

Panitumumab (ABX-EGF) هو جسم مضاد أحادي النسيلة IgG2 بشري كامل مضاد لـ EGFR مع نشاط مضاد للورم. البانيتوماب يمنع تكاثر الخلايا السرطانية والبقاء على قيد الحياة وتكوين الأوعية. يمكن استخدام البانيتوماب في البحث عن السرطانات ، مثل سرطان القولون.

Products are for research use only. Not for human use. We do not sell to patients.

Panitumumab التركيب الكيميائي

Cas No.: 339177-26-3

الحجم السعر المخزون الكميّة
1mg
165٫00
متوفر
5mg
504٫00
متوفر
10mg
806٫40
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Panitumumab (ABX-EGF) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab can be used in the research of cancers, such as colon cancer[1][2][4].

Panitumumab (2 nM-2 μM, 3 h) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].

Western Blot Analysis[3]

Cell Line: EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells
Concentration: 2, 20, 200, 2000 nM
Incubation Time: 3 h
Result: Inhibited ligand-induced autophosphorylation of EGFR.

Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003)[1].

Animal Model: NCI-H1975 and NCI-H1650 xenografts[3]
Dosage: 25, 100, or 500 μg/mouse
Administration: Intraperitoneal injection (i.p.), twice a week
Result: Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.
Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.

مراجعات

Review for Panitumumab

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Panitumumab

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.